Abstract:Abstract Background The extracellular signal-regulated kinase-1 and 2 (ERK1/2) proteins play an important role in cancer cell proliferation and survival. ERK1/2 proteins also are important for normal cell functions. Thus, anti-cancer therapies that block all ERK1/2 signaling may result in undesirable toxicity to normal cells. As an alternative, we have used computational and biological approaches to identify low-molecular weight compounds that have the potential to interact with unique ERK1/2 docking sites and selectively inhibit interactions with substrates involved in promoting cell proliferation. Methods Colony formation and water soluble tetrazolium salt (WST) assays were used to determine the effects of test compounds on cell proliferation. Changes in phosphorylation and protein expression in response to test compound treatment were examined by immunoblotting and in vitro kinase assays. Apoptosis was determined with immunoblotting and caspase activity assays. Results In silico modeling was used to identify compounds that were structurally similar to a previously identified parent compound, called 76 . From this screen, several compounds, termed 76.2 , 76.3 , and 76.4 sharing a common thiazolidinedione core with an aminoethyl side group, inhibited proliferation and induced apoptosis of HeLa cells. However, the active compounds were less effective in inhibiting proliferation or inducing apoptosis in non-transformed epithelial cells. Induction of HeLa cell apoptosis appeared to be through intrinsic mechanisms involving caspase-9 activation and decreased phosphorylation of the pro-apoptotic Bad protein. Cell-based and in vitro kinase assays indicated that compounds 76.3 and 76.4 directly inhibited ERK-mediated phosphorylation of caspase-9 and the p90Rsk-1 kinase, which phosphorylates and inhibits Bad, more effectively than the parent compound 76 . Further examination of the test compound's mechanism of action showed little effects on related MAP kinases or other cell survival proteins. Conclusion These findings support the identification of a class of ERK-targeted molecules that can induce apoptosis in transformed cells by inhibiting ERK-mediated phosphorylation and inactivation of pro-apoptotic proteins.

ERK1/2 MAP Kinases in Cell Survival and Apoptosis

Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

ERK/MAPK signalling pathway and tumorigenesis

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)

ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

Role of Mitogen‐activated Protein Kinases in Activation‐induced Apoptosis of T Cells

ERK signalling: a master regulator of cell behaviour, life and fate

The Phd Domain Of Mekk1 Acts As An E3 Ubiquitin Ligase And Mediates Ubiquitination And Degradation Of Erk1/2

ERK MAP kinase in G1 cell cycle progression and cancer

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy

Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK

The Role of Mitogen-Activated Protein Kinase(mapk) Pathway in the Action Mechan Ism of PYM-induced KB Cells Apoptosis

The Specificity of Extracellular Signal-regulated Kinase 2 Dephosphorylation by Protein Phosphatases

Characterization of ERK Docking Domain Inhibitors that Induce Apoptosis by Targeting Rsk-1 and Caspase-9

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control

A Molecular Link Between E2F-1 and the MAPK Cascade.

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy

The MEK/ERK Network as a Therapeutic Target in Human Cancer